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Phase Observational Study of the MitraClip System in Europe), a European prospective, multicenter, nonrandomized
post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).Background MitraClip has been increasingly performed in Europe after approval; the ACCESS-EU registry provides a snapshot of
the real-world clinical demographic data and outcomes.Methods A total of 567 patients with signiﬁcant mitral valve regurgitation (MR) underwent MitraClip therapy at 14 European
sites. Mean logistic European System for Cardiac Operative Risk Evaluation at baseline was 23.0  18.3; 84.9%
patients were in New York Heart Association functional class III or IV, and 52.7% of patients had an ejection
fraction 40%.Results The MitraClip implant rate was 99.6%. A total of 19 patients (3.4%) died within 30 days after the MitraClip
procedure. The Kaplan-Meier survival at 1 year was 81.8%. Intensive care unit and hospital length of stay was
2.5  6.5 days and 7.7  8.2 days, respectively. Single leaﬂet device attachment was reported in 27 patients
(4.8%). There were no MitraClip device embolizations. Thirty-six subjects (6.3%) required mitral valve surgery within
12 months after the MitraClip implant procedure. There was improvement in the severity of MR at 12 months,
compared with baseline (p < 0.0001), with 78.9% of patients free from MR, severity of >2þ at 12 months.
At 12 months, 71.4% of patients had New York Heart Association functional class II or class I. Six-min-walk-test
improved 59.5  112.4 m, and Minnesota-living-with-heart-failure score improved 13.5  20.5 points.Conclusions In the real-world, post-approval experience in Europe, patients undergoing the MitraClip therapy are high-risk, elderly
patients, mainly affected by functional MR. In this patient population, the MitraClip procedure is effective with low
rates of hospital mortality and adverse events. (J Am Coll Cardiol 2013;62:1052–61) ª 2013 by the American
College of Cardiology Foundationfaele, Milan, Italy; yDepartment of Cardiology,
k; zDepartment of General and Interventional
Hamburg, Germany; xDepartment of Cardi-
amburg, Germany; kDeutsches Herzzentrum
Centre Brandenburg, Bernau/Berlin, Germany;
ital Heart Disease Programme, Invasive Cardi-
o Hospital, University of Catania, Catania, Italy;
yyCardioVascular Center Frankfurt, Frankfurt,
Kliniken GmbH (Academic Teaching Hospital
urg), Bad Segeberg, Germany; xxMedizinische
ivision of Cardiology, Fondazione Cardiocentro
e {{Heart Centre, Georg-August University,
-EU registry has been sponsored by Abbott
Vascular, Inc. Dr. Maisano has received consulting fees from Abbott Vascular, Med-
tronic, ValtechCardio, and St. Jude Medical; is a founder of 4Tech; and has received
royalties from Edwards Lifesciences. Dr. Franzen has received research grants, proc-
toring honoraria, and lecture fees from Abbott Vascular. Dr. Baldus has received
research grants and lecture fees from Abbott Vascular. Dr. Schäfer has received
consulting fees from Abbott Vascular. Dr. Hausleiter has received speaker honoraria
from Abbott Vascular. Dr. Butter has received research grants from Abbott Vascular.
Dr. Sievert has received study honoraria, travel expenses, and consulting fees from
Abbott Vascular, Access Closure, AGA, Angiomed, Aptus, Arstasis, Atritech, Atrium,
Avinger, Bard, Boston Scientiﬁc, Bridgepoint, Cardiac Dimensions, CardioKinetix,
CardioMEMS, Coherex, Contego, CSI, CVRx, EndoCross, EndoTex, Epitek, ev3,
FlowCardia, Gore, Guidant, Guided Delivery Systems, Inc., InSeal Medical, Lumen
Biomedical, HLT, Kensey Nash, Kyoto Medical, Lifetech, Lutonix, Maya Medical,
Abbreviations
and Acronyms
CI = conﬁdence interval
DMR = degenerative mitral
valve regurgitation
EF = ejection fraction
EuroSCORE = European
System for Cardiac
Operative Risk Evaluation
FMR = functional mitral
valve regurgitation
MLHFQ = Minnesota Living
JACC Vol. 62, No. 12, 2013 Maisano et al.
September 17, 2013:1052–61 Percutaneous Mitral Interventions in the ACCESS-EU Study
1053MitraClip therapy (Abbott Vascular, Inc., Santa Clara,
California) is a percutaneous treatment for mitral valve re-
gurgitation (MR) based on edge-to-edge surgical technique
pioneered by Alﬁeri et al. (1,2). MitraClip therapy has been
successfully used to treat either functional (FMR) or
degenerative mitral valve regurgitation (DMR) (3–7). The
EVEREST trial (Endovascular Valve Edge-to-edge REpair
STudy) compared safety and efﬁcacy of percutaneous versus
surgical therapy in a cohort of operable patients mainly with
DMR (3). Because it only enrolled operable patients, the
outcomes of the EVEREST trial could not be applicable
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regurgitation
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attachmentTo provide an up-to-date snapshot of the current practice
in Europe, the ACCESS-EU study (ACCESS-Europe A
Two-Phase Observational Study of the MitraClip System in
Europe), a bi-phase European prospective, multicenter,
nonrandomized post-approval study of MitraClip therapy
was designed. The primary objective of the ACCESS-EU
Phase I study was to gain information with regard to the
use of the MitraClip system in Europe with respect to health
economics and clinical care, to deﬁne demographic data of
patients, and to provide further evidence of the safety and
effectiveness of the MitraClip System in a real-world setting.
In addition to theMitraClip device group, 2 standard therapy
concurrent comparator groups (medically managed patients
and patients who have undergone mitral valve surgery for
MR) have been enrolled and evaluated primarily from
a health economic perspective. No selection criteria to allo-
cate patients in the MitraClip versus standard therapy groups
were pre-speciﬁed, and the indication was based on indi-
vidual clinical judgment. The present paper reports exclu-
sively on patients who underwent percutaneous treatment
with the MitraClip device.
Methods
TheMitraClip System received CEMark inMarch 2008, and
commercialization was initiated in September 2008. The
technical details of the device and of the procedure have been
previously described (3). The ACCESS-EU Phase I study
began enrolling patients in Europe in April 2009. Enrollment-
-
s
f
-
,in ACCESS-EU Phase I was
completed onApril 13, 2011.This
report includes baseline through
12-month clinical data collected as
of June 15, 2012. Figure 1 presents
patient accountability through 12
months.
Patient screening, enrollment,
treatment, and follow-up. In-
dication to MitraClip therapy was
given according to local institu-
tional practice in consideration
of current CE Mark approved
labeling and theMitraClip System
Instructions for Use. Eligible
patients included those with sym-
ptomatic MR or asymptomatic
moderate-to-severe (3þ) or severe
(4þ) MR. Transthoracic and
transesophageal echocardiogram
studies were evaluated at baseline
to assess patient eligibility. All
patients provided written informed consent before their
enrollment in the study (Fig. 2). Patients were evaluated at
baseline through 12 months after enrollment. The Minnesota
Living with Heart Failure quality of life questionnaire
(MLHFQ) and 6-min walk test (6MWT) were administered
at baseline and at 6 and 12 months. Enrollment in the study is
complete.
Statistical considerations. Baseline and demographic qual-
itative variables were expressed as percentages, and quan-
titative variables were expressed as mean  SD or median
(25th to 75th interquartile range). The MR severity was
compared between baseline, discharge, and 6 and 12 months
with Bowker’s test. Changes in 6MWT distance and quality
of life between baseline and 6 and 12 months were analyzed
with paired t tests. Survival rates up to 12 months were
presented as Kaplan-Meier curves. Differences were con-
sidered statistically signiﬁcant at p values <0.05. The data
were analyzed with SAS statistical software (version 9.1.3,
SAS Institute, Inc., Cary, North Carolina).
Data collection. Demographic data, acute procedural
results, and post-procedural follow-up data were collected by
study personnel at investigational sites and entered onto
electronic Case Report Forms. Echocardiographic studies
and quantitative assessment of MR were performed by the
study sites. Data management was performed by MedPass
International–ACCESS-EU Data Coordinating Center.
Results
A total of 567 patients have been enrolled at 14 European
sites. The baseline characteristics, including site-reported
severity and etiology of MR are summarized in Table 1
(displaying also data from the EVEREST II and EVER-
EST high-risk studies for comparison). The mean logistic
Figure 1 Patient Enrollment and Follow-Up Status
The ACCESS-EU Phase I study enrolled 567 patients between April 2009 and April
2011. Complete patient accountability from baseline through 12 months is shown.
There were 58 patient withdrawals and 98 deaths through 12 months.
Figure 2
Patient Screening, Enrollment, Treatment,
and Follow-Up
Patients enrolled in the ACCESS-EU study are a subset of patients treated under
commercial use in Europe. Patients who signed the informed consent form and
have attempted placement of the MitraClip device (Abbott Vascular, Inc., Santa
Clara, California) were considered enrolled in the ACCESS-EU study. All enrolled
patients were evaluated at baseline, discharge, 6 months, and 12 months.
MLHF ¼ Minnesota Living with Heart Failure questionnaire; NYHA ¼ New York
Heart Association; TEE ¼ transesophageal echocardiogram; TTE ¼ transthoracic
echocardiogram.
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1054European System for Cardiac Operative Risk Evaluation
(EuroSCORE) at baseline was 23.0  18.3 with 44.6% of
patients having a baseline logistic EuroSCORE 20%.
Patients with FMR tended to have more comorbidities and
had a higher logistic EuroSCORE. Most ACCESS-EU
Phase I patients had symptoms of heart failure at baseline,
with 69.9% in New York Heart Association (NYHA)
functional class III, and 14.9% in class IV. Many patients
had some degree of left ventricular dysfunction, with a large
proportion (52.7%) having a left ventricular ejection fraction
(EF) 40%. Eleven percent had an EF 20%. Twenty-
seven patients (4.9%) were in cardiogenic shock at the time
of the index procedure.
The MitraClip device implant rate was 99.6% with only 2
patients not successfully implanted with a MitraClip device.
One patient had a pre-existing patent foramen ovale and
a severely dilated left atrium with a mobile septum and
developed a large atrial septal defect as the consequence of
the guide catheter manipulations. The defect was determinedto be too large to treat with catheter-based techniques. The
patient underwent successful surgical mitral valve replace-
ment and atrial septal repair. The second patient did not
receive a MitraClip device, due to an inability to adequately
reduce MR. This patient also underwent a successful mitral
valve surgery. In the remaining patients, 60.1% received 1
MitraClip device, 36.7% received 2 devices, and a very small
proportion (<3%) received 3 or more devices. Procedural
results, including procedure time, contrast volume, and ﬂuo-
roscopy duration, are summarized in Table 2.
JACC Vol. 62, No. 12, 2013 Maisano et al.
September 17, 2013:1052–61 Percutaneous Mitral Interventions in the ACCESS-EU Study
1055Safety. There was no incidence of death, stroke, or res-
piratory failure intra-procedurally and in the immediate
post-operative period after the MitraClip procedure. Myo-
cardial infarction was reported acutely in 1 patient, and a small
proportion of patients experienced cardiac tamponade (0.9%)
or the need for resuscitation (1.1%). Site-reported safety
outcomes at 30 days are presented in Table 3. A total of 19
patients (3.4%) died within the 30 days after the MitraClip
procedure. The site-reported causes of death for these
patients were: cardiac (42%, 8 of 19); multi-organ failure
(16%, 3 of 19); sepsis (11%, 2 of 19); pneumonia (5%, 1 of
19); respiratory failure (5%, 1 of 19); pulmonary embolism
(5%, 1 of 19); cerebral (5%, 1 of 19); and unknown causes
(11%, 2 of 19). Figure 3 shows the Kaplan-Meier freedom
from mortality at 12 months post-procedure. The Kaplan-
Meier estimate of freedom from mortality at 6 and 12
months is 88.2% (95% conﬁdence interval [CI]: 85.1% to
90.6%) and 81.8% (95% CI: 78.1% to 84.8%), respectively. A
total of 98 (17.3%) deaths were reported within 12 months of
the MitraClip procedure.
The mean duration of time that patients spent in the
intensive care unit after the MitraClip procedure was 2.5 
6.5 days with a median of 1.0 day. Patients were discharged
from the hospital an average of 7.7  8.2 days with a median
of 6.0 days after the MitraClip procedure. The large majority
of patients (79.2%) were discharged home without home
health care, whereas 17.1% were discharged to a skilled
nursing facility.
Single leaﬂet device attachment (SLDA), deﬁned as the
loss of insertion of a single leaﬂet from the MitraClip device
with ongoing insertion of the opposing leaﬂet was reported
in 27 patients (4.8%). All but 1 SLDA case were diagnosed
within 6 months from the index procedure. Of the 27
patients that had SLDAs, 10 underwent a second MitraClip
procedure, no action was taken in 11 patients, 6 patients had
mitral valve repair or replacement surgery, and 1 patient had
additional MitraClip devices implanted during the index
procedure. There have been no reports of MitraClip device
embolization in the ACCESS-EU Study.
Thirty-six subjects (6.3%) underwent a mitral valve surgery
within 12 months after the MitraClip implant procedure.
Nineteen patients (3.4%) underwent a second intervention to
place an additionalMitraClip device to reduceMR.Of the 19
attempts to further reduce MR with a second intervention to
place a MitraClip device, 14 (74%) were successful.
Efﬁcacy. Acute hemodynamic measurements obtained be-
fore MitraClip procedure and at least 10 min after MitraClip
device deployment were available on a subset of patients. After
the MitraClip procedure, mean cardiac output increased by
0.7 l/min, from 3.7 1.5 l/min to 4.4 1.9 l/min. Pulmonary
Capillary Wedge Pressure V-wave decreased by 3.5 mm Hg,
from 23.0  10.8 mm Hg to 19.5  9.1 mm Hg. All other
hemodynamic parameters remained stable post-implant.
Most patients (91.2%) achieved MR reduction to 2þ or
less at discharge, and 50.9% had an MR severity rating of
1þ or less. There was improvement in the severity of MRat 12 months compared with baseline (p < 0.0001), with
79.8% (313 of 392) of patients free from MR severity of
>2þ at 6 months (Fig. 4, Table 4). At 1 year from the
procedure, 78.9% (258 of 327) of patients were free from
MR severity of >2þ (p < 0.0001). Eighty-eight percent of
patients experienced at least a 1-grade MR improvement
from baseline to 12 months, 53% experienced 2-or-more-
grade improvement, and ﬁnally, 16% of patients improved
by 3 or more grades.
At 12 months, 71.4% (245 of 343) of patients had
NYHA functional class II or class I.
The 6MWT (matched data available on 261 patients)
(Fig. 5) improved 56.4  120.1 m (95% CI: 41.8 to 71.0,
p ¼ 0.0006) at 6 months (322.0  124.8 m) as compared
with baseline (265.5  120.0 m). At 12 months (matched
data available on 216 patients), the improvement in 6MWT
was 59.5  112.4 m (95% CI: 44.5 to 74.6, p < 0.0001) from
274.7  118.7 m at baseline to 334.2  127.9 m at 12
months. There was no signiﬁcant improvement in the distance
walked during the 6MWT between 6 and 12 months.
The MLHFQ went from 41.2  19.1 at baseline to
28.9  20.7 at 6 months for patients with matched data
(n ¼ 311), representing an improvement of 12.3  20.9
points (95% CI: 14.6 to 10.0, p < 0.0001). The MLHFQ
score improved 13.5  20.5 points (95% CI: 11.0 – 16.0,
p < 0.0001) from baseline (41.6  18.9) to 12 months
(28.1  20.1) in 264 patients with paired data. The
MLHFQ score improved by 0.4  16.2 points between 6
and 12 months (p ¼ 0.0002).
Discussion
The ACCESS-EU study is the largest database of Mitra-
Clip therapy reported to date and demonstrates that most
patients currently treated in Europe have a high surgical risk
proﬁle. Nonetheless, the procedure is safe, with low adverse-
event rate at 30 days and 12 months. MitraClip therapy is
effective in most patients, with sustained and meaningful
improvement of hemodynamic and functional status at 12
months from the procedure.
The ACCESS-EU study offers a precious snapshot of the
current population of patients undergoing transcatheter
treatment of MR in Europe: the mean age was 74 years (45%
of patients were older than 75 years); most patients had FMR
(77%) and low EF (53% of patients with an EF 40%) and
presented with multiple comorbidities, including coronary
artery disease (63%), hypertension (76%), atrial ﬁbrillation
(68%), and renal disease (42%). Overall, 40% of patients
had some form of heart rhythm management, although only
11% of patients had a biventricular-pacing device implanted
before MitraClip procedure. The vast majority of patients
were highly symptomatic (85% of patients were in NYHA
functional class III or IV at baseline), a condition that has
been associated with worse outcomes (4,8).
This population is different from the one treated in the
EVEREST II RCT trial (EVEREST II Randomized
Table 1 Baseline Characteristics
Characteristic*
ACCESS-EU Phase I EVEREST II Randomized Clinical Trial EVEREST II High Risk Study
All Patients (N ¼ 567) FMR Patients (n ¼ 393) DMR Patients (n ¼ 117) MitraClip Patients (n ¼ 184) MitraClip Patients (n ¼ 78)
Age, yrs 73.7  9.6 (567) 73.0  8.9 (393) 75.6  12.1 (117) 67.3.0  12.8 (184) 76.7  9.8 (78)
Patients over 75 yrs of age 45.1% (256/567) 40.7% (160/393) 61.5% (72/117) 29.9% (55/184) 61.5% (48/78)
Sex
Female 36.2% (205/567) 32.1% (126/393) 49.6% (58/117) 37.5% (69/184) 37.2% (29/78
Male 63.8% (362/567) 67.9% (267/393) 50.4% (59/117) 62.5% (115/184) 62.8% (49/78)
Comorbidities
Congestive heart failure 70.1% (397/566) 70.7% (277/392) 62.4% (73/117) 90.8% (167/184) 100.0% (78/78)
Coronary artery disease 62.7% (354/565) 68.2% (267/391) 41.0% (48/117) 47.0% (86/183) 84.2% (64/76)
Myocardial infarction 32.0% (175/547) 35.0% (132/377) 21.6% (25/116) 21.9% (40/183) 55.8% (43/77)
Atrial ﬁbrillation 67.7% (356/526) 69.3% (248/358) 58.8% (67/114) 33.9% (59/174) 61.6% (45/73)
Cerebrovascular disease 12.9% (73/566) 13.8% (54/392) 10.3% (12/117) 7.6% (14/184) 17.9% (14/78)
Cardiomyopathy 46.2% (259/561) 54.4% (212/390) 22.6% (26/115) 17.9% (33/184) 51.3% (40/78)
Hypertension 76.1% (429/564) 76.2% (298/391) 75.0% (87/116) 72.3% (133/184) 89.7% (70/78)
Diabetes 29.6% (168/567) 34.1% (134/393) 14.5% (17/117) 7.6% (14/184) 41.0% (32/78)
Renal disease 41.6% (236/567) 48.1% (189/393) 25.6% (30/117) 3.3% (6/184) 23.1% (18/78)
Peptic ulcer disease 5.1% (29/565) 6.6% (26/391) 2.6% (3/117) 6.0% (11/183) 9.1% (7/77)
Cardiogenic shock 4.9% (27/554) 5.4% (21/386) 2.6% (3/116) d d
Chronic pulmonary disease 19.0% (107/562) 20.3% (79/389) 14.7% (17/116) 14.8% (27/183) 34.7% (27/78)
Previous coronary artery bypass grafting 28.9% (164/567) 33.3% (131/393) 17.1% (20/117) 20.7% (38/184) 55.1% (43/78)
Previous percutaneous intervention 38.2% (213/558) 40.4% (156/386) 27.6% (32/116) 24.0% (44/183) 38.5% (30/78)
Cardiac rhythm device implant
CRT 10.7% (59/552) 12.8% (49/382) 1.7% (2/115) N/A N/A
ICD 16.7% (92/552) 20.2% (77/382) 3.5% (4/115) 7.2% (13/181) 13.0% (10/77)
Pacemaker 12.7% (70/552) 13.1% (50/382) 12.2% (14/115) 4.4% (8/181) 22.1% (17/77)
Logistic EuroSCORE 23.0  18.3 (567) 24.8  18.9 (393) 15.5  13.3 (117) d d
Logistic EuroSCORE 20% 44.6% (253/567) 48.4% (190/393) 28.2% (33/117) d d
STS mortality risk d d d 5.0  4.0 (184) 14.2  8.2 (78)
STS mortality risk 12% d d d 6.0% (11) 61.5% (48)
LVEF
10%–20% 11.0% (62/562) 13.4% (52/388) 3.4% (4/117) d d
20%–30% 23.3% (131/562) 30.9% (120/388) 0.9% (1/117) d d
30%–40% 18.3% (103/562) 21.9% (85/388) 5.1% (6/117) d d
>40% 47.3% (266/562) 33.8% (131/388) 90.6% (106/117) d d
Mean  SD (n) d 60.0  10.1 (182) 54.4  13.7 (78)
NYHA
I 1.3% (7/549) 0.3% (1/379) 5.2% (6/115) 9.2% (17/184) 0.0% (0/78)
II 13.8% (76/549) 12.4% (47/379) 20.9% (24/115) 39.7% (73/184) 10.3% (8/78)
III 70.0% (384/549) 70.7% (268/379) 67.0% (77/115) 44.6% (82/184) 60.3% (47/78)
IV 14.9% (82/549) 16.6% (63/379) 7.0% (8/115) 6.5% (12/184) 29.5% (23/78)
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1057Clinical Trial), who were slightly younger (71 years, on
average), less symptomatic (52% patients in class III to IV),
had the opposite MR etiology distribution (73.4% DMR),
had mostly preserved EF (average 60.0  10.1%), and
presented less comorbidities: coronary disease in 47%; atrial
ﬁbrillation in 34%, while renal insufﬁciency was a protocol
exclusion criterion. Two ACCESS-EU contributing centers
have recently demonstrated that exclusion criteria for the
EVEREST II trial would have been met in 73% (9) and
80% (10) of patients, respectively, predominantly because of
ventricular dysfunction.
The difference in the respective patient populations
treated with the MitraClip device in the ACCESS-EU and
EVEREST II RCT studies is not unexpected, because
conventional surgery is very effective in DMR, and the main
unmet need for low-risk procedures is for patients with
FMR, with low EF, and multiple comorbidities. As a result,
the average logistic EuroSCORE was 23.0  18.3, and 45%
of patients had a EuroSCORE >20%.
The ACCESS-EU patients presented in this report have
more in common with the MitraClip patients treated in the
EVEREST II High Risk Study (11). These patients were
indeed older (mean age of 77), presented with multiple
comorbidities, and were determined to be at high surgical risk
on the basis of a Society of Thoracic Surgeons score 12%
or on the basis of the estimate of mortality of a surgeon.
The EVEREST II High Risk Study patients were also more
often symptomatic (90% had class III to IV) and were
predominantly FMR (59%).
Despite the higher risk proﬁle of patients enrolled in the
ACCESS-EU study, the rate of adverse events remained
low: 30-day mortality was 3.4%, with main cause being
cardiac and low cardiac output state resulting in multi-organ
failure, sepsis, and respiratory failure.
Compared with early reports (5), length of stay was
longer, likely reﬂective of baseline high-risk status and
standard treatment practices in Europe. However, a signiﬁ-
cant proportion of patients have been discharged home
without the need for home health care. The data suggest that
patients undergoing the MitraClip procedure tolerated and
recovered quickly from the procedure.
Although not prospectively speciﬁed in the ACCESS-
EU study, procedural success (deﬁned as successful
implantation of the MitraClip device and MR reduction to
2þ or less in the EVEREST trials) was obtained in 91% of
patients. The rate of patients with MR 3þ at discharge in
the current registry was 9%, an improvement from earlier
reports reﬂecting group learning and accumulated experi-
ence. A recent publication from a single center cohort of
75 patients has examined the effects of learning curve and
has demonstrated a substantial effect of learning on safety as
well as on acute and mid-term efﬁcacy of the procedure (9).
Fluoroscopy time (29 min) was a relatively small percentage
(24.9%) of the overall procedure time. In approximately
two-thirds (68.3%) of ACCESS patients, no contrast was
used, which might be reﬂective of the high risk proﬁle
Table 2 Procedure Time, Contrast Volume, and Fluoroscopy Duration
ACCESS-EU Phase I
All Patients (N ¼ 567) FMR Patients (n ¼ 393) DMR Patients (n ¼ 117)
Procedure time* 100.0 (15.0, 390.0) 93.0 (20.0, 342.0) 100.0 (15.0, 390.0)
Contrast volume (ml) 0.0 (0.0, 308.0) 0.0 (0.0, 308.0) 0.0 (0.0, 280.0)
Fluoroscopy duration 25.0 (0.0, 152.0) 26.0 (0.0, 152.0) 22.0 (5.0, 83.0)
Values are median (minimum, maximum). *Procedure time is deﬁned as the time from start of the transseptal procedure until the time the steerable
guide catheter is removed.
Abbreviations as in Table 1.
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1058and high rate of renal disease observed in this patient
population.
There were 27 cases (4.8%) of SLDA reported at 12
months in the ACCESS-EU study. Most SLDA occurred
early (within 6 months from the index procedure), reﬂecting
the relationship with intra-procedural factors. Interestingly,
one-half of the patients with SLDA were treated percuta-
neously with another clip implant (12): either within the
index procedure (n ¼ 1) or at a later stage (n ¼ 10). The
SLDA was the main cause leading to repeat MitraClip
implantation due to residual or recurrent MR. Overall, the
second MitraClip procedure was successful in approximately
3 of 4 patients. Only 6 of 27 patients with SLDA required
valve surgery (13). The SLDA is primarily related to the
challenge of assessing leaﬂet insertion at the time of the
procedure, and it is more often seen in patients with more
complex anatomy and EVEREST II exclusion criteria.
With experience and improved imaging guidance, the risk of
SLDA might become less probable. In particular, 3-
dimensional echocardiography (14), with x-plane features,
allows appropriate scanning of the clip area in multiple
planes to better analyze leaﬂet insertion.
The rate of valve surgery at 12 months for failed Mitra-
Clip repair was 6.3%, lower than that reported in the
EVEREST II RCT (20% in the intention to treat analysis).
However, this rate might underestimate the proportion of
patients with recurrent/residual MR, due to the risk of
surgery.
In the EVEREST II trial, MitraClip was inferior to
surgery in the overall population comparison of the primaryTable 3 Site-Reported Safety Outcomes at 30 Days and 12 Months
Safety Outcomes
30 Days
All Patients
(N ¼ 567)
FMR Patients
(n ¼ 393)
DMR P
(n ¼
Death 3.4% (19/567) 2.8% (11/393) 6.0% (
Stroke 0.7% (4/567) 0.5% (2/393) 0.9% (
Myocardial infarction 0.7% (4/567) 0.8% (3/393) 0.9% (
Renal failure 4.8% (27/567) 5.1% (20/393) 2.6% (
Respiratory failure 0.7% (4/567) 1.0% (4/393) 0% (
Need for resuscitation 1.8% (10/567) 2.3% (9/393) 0.9% (
Cardiac tamponade 1.1% (6/567) 1.0% (4/393) 0.9% (
Bleeding complications 3.9% (22/567) 3.8% (15/393) 3.4% (
Values are % (n/N).
Abbreviations as in Table 1.efﬁcacy endpoint (freedom from death, mitral valve surgery,
and recurrent MR 3þ). However, in an exploratory
intention-to-treat analysis, surgery was nonsuperior in
patients who were older than 70 years (p ¼ 0.009) and in
patients with FMR, as compared with DMR (p ¼ 0.02).
Interestingly, these patients are the most commonly treated
in the ACCESS-EU study.
The European study demonstrated a clinically meaningful
improvement of MR, functional status, and quality of life at
6 and 12 months after the procedure in the overall pop-
ulation. Four of 5 patients treated had MR 2þ at 12
months from the index procedure. Improvement of MR
obtained at 6 months remained stable at 12 months, sug-
gesting stability of results. Improvement of at least 1 degree
of MR was observed in 88% (289 of 327) of patients, and at
least 2 degrees reduction was observed in 53% (173 of 327)
of patients. Unfortunately, the ACCESS-EU study echo-
cardiographic data were not assessed by a core laboratory. In
addition, the challenge of grading MR after a double oriﬁce
repair makes the MR reduction endpoint a weak measure of
the efﬁcacy of the procedure. Functional MR is known to
be ﬂuctuant and load-dependent, therefore its measure is
difﬁcult to standardize.
Functional outcomes are a more appropriate way of
assessing the value of MitraClip therapy in the FMR pop-
ulation, where standardization of echo assessment is not
feasible. Besides NYHA functional class improvement, more
objective outcomes included the increased distance of the
6MWT and the improved MLHFQ score at 6 and 12
months from MitraClip implant. Functional improvementACCESS-EU Phase I
12 Months
atients
117)
All Patients
(N ¼ 567)
FMR Patients
(n ¼ 393)
DMR Patients
(n ¼ 117)
7/117) 17.3% (98/567) 17.0% (67/393) 17.1% (20/117)
1/117) 1.1% (6/567) 1.0% (4/393) 0.9% (1/117)
1/117) 1.4% (8/567) 1.8% (7/393) 0.9% (1/117)
3/117) 8.6% (49/567) 9.4% (37/393) 6.0% (7/117)
0/117) 0.9% (5/567) 1.0% (4/393) 0.0% (0/117)
1/117) 2.1% (12/567) 2.8% (11/393) 0.9% (1/117)
1/117) 1.2% (7/567) 1.0% (4/393) 0.9% (1/117)
4/117) 4.8% (27/567) 4.6% (18/393) 3.4% (4/117)
Figure 3
Kaplan-Meier Freedom From All-Cause Mortality
at 12 Months
A total of 98 (17%) deaths were reported within 12 months of the MitraClip
procedure. The Kaplan-Meier estimate of freedom from mortality at 12 months is
81.8% (95% conﬁdence interval: 78.1% to 84.8%).
Figure 4 Severity of Mitral Regurgitation at Baseline, Discharge, 6 a
(A) Mitral regurgitation severity at baseline, discharge, 6 and 12 months (unpaired data)
to 6 months, and baseline to 12 months (paired data).
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1059was also associated with favorable 12-month survival of
81.8% (95% CI: 78.1% to 84.8%); however, in absence of
a relevant comparator group, any survival beneﬁt is difﬁcult
to estimate and will require properly designed studies
randomized against optimal medical therapy. In the DMR
patients, residual MR is usually related to an untreated
lesion, mainly residual prolapsing tissue, at risk of disease
progression. Therefore, residual MR in the DMR pop-
ulation could be a more meaningful outcome to monitor,
particularly in the younger population.
Study limitations. The ACCESS-EU phase I registry has
several limitations, which will be addressed by the phase II
study. The main limitation is the lack of a core-laboratory
adjudication of echocardiographic parameters. Details with
regard to morphological evaluation (number of segments
involved, annular dimensions, jet geometry) were not recor-
ded. These data would have great impact on deﬁning anat-
omical risk factors for success. In addition, echocardiographic
data on baseline and follow-up ventricular dimensions were
insufﬁcient to prove favorable geometrical remodeling in
this high-risk population. Another limitation of the study,
which is related to the post-market nature of the study, is
that there were no pre-deﬁned enrollment criteria: indicationnd 12 Months
. (B) Change in mitral regurgitation severity from baseline to discharge, baseline
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Figure 5
Change in 6-Min Walk Distance From
Baseline to 6 and 12 Months
Change in 6-min walk test distance from baseline to 6 months and
baseline to 12 months (paired data).
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1060for MitraClip therapy as well as anatomical eligibility were
left to the individual centers, according to their experience.
However, this limitation adds value to the data presented,
because outcomes reﬂect the real-world application of the
therapy. Finally, because there was no pre-speciﬁed medical
therapy strategy, changes in medical therapy during the
conduction of the study might have affected outcomes.Conclusions
In the real-world, post-approval experience in Europe,
patients undergoing the MitraClip therapy are high-risk,
elderly patients, mainly affected by FMR. This has repre-
sented a signiﬁcant shift from the population originally
investigated in the EVEREST II RCT study and is in line
with the patients enrolled in the EVEREST II High Risk
Study and treated in the REALISM study (EVEREST II
Continued Access Study). The unmet need for a safer
solution in high-risk patients has driven this change in
practice, although not supported by published evidence.
The ACCESS-EU study is the ﬁrst large database report-
ing outcomes of the MitraClip in a high-risk population of
patients with prevalence of FMR. In this patient pop-
ulation, the MitraClip procedure is safe, with low rates of
hospital mortality and adverse events. Most patients have
been treated successfully, which might be attributed in part
to improved learning curve. As a result, meaningful clinical
improvement has been observed in most patients in the
mid-term, with objective improvement of quality of life and
functional status. Longer-term follow-up and more in-
depth analysis of the data will provide useful insights of
the MitraClip therapy in the real world. The inferences
from this study are fundamental for designing future trials
JACC Vol. 62, No. 12, 2013 Maisano et al.
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1061for both the FMR and DMR pathologies and support the
indication to MitraClip therapy in high-risk patients with
either FMR or DMR.Reprint requests and correspondence: Dr. Francesco Maisano,
Department of Cardiac Surgery, Hospital San Raffaele, Via
Olgettina 60, 20132 Milan, Italy. E-mail: francesco.maisano@hsr.it.
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